Editas Medicine Reveals Promising Gene Therapy Trial Results
Company Announcements

Editas Medicine Reveals Promising Gene Therapy Trial Results

Editas Medicine (EDIT) has issued an update.

Editas Medicine, Inc. has unveiled promising new data from clinical trials of its gene-editing therapy, Reni-cel, for severe sickle cell disease and transfusion-dependent beta thalasemia. Patients in the RUBY trial experienced no vaso-occlusive events and significant improvements in hemoglobin levels, while those in the EdiTHAL trial achieved transfusion independence with robust hemoglobin increases. Both trials reported successful engraftment, no serious adverse events, and a safety profile in line with current gene therapy standards.

For a thorough assessment of EDIT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyEditas Medicine price target lowered to $5 from $8 at RBC Capital
TheFlyRaymond James downgrades Editas on extended development timelines
TheFlyEditas Medicine downgraded to Market Perform from Outperform at Raymond James
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App